US Patent

US8357693 — Pharmacokinetically improved compounds

Method of Use · Assigned to Surface Logix Inc · Expires 2034-06-20 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of modulating the pharmacokinetic and/or pharmacodynamic properties of ROCK1 and ROCK2 inhibitors, useful for treating disease.

USPTO Abstract

The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.

Drugs covered by this patent

belumosudil-mesylate (BELUMOSUDIL MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4259`	—	belumosudil-mesylate

Patent Metadata

Patent number: US8357693
Jurisdiction: US
Classification: Method of Use
Expires: 2034-06-20
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Surface Logix Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.